nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLC22A8—Adefovir Dipivoxil—hepatitis B	0.236	0.358	CbGbCtD
Dabrafenib—SLC22A6—Adefovir Dipivoxil—hepatitis B	0.165	0.25	CbGbCtD
Dabrafenib—ABCG2—Lamivudine—hepatitis B	0.119	0.181	CbGbCtD
Dabrafenib—SLC22A6—Lamivudine—hepatitis B	0.0965	0.146	CbGbCtD
Dabrafenib—ABCB1—Lamivudine—hepatitis B	0.043	0.0652	CbGbCtD
Dabrafenib—Disease progression—Telbivudine—hepatitis B	0.0131	0.0638	CcSEcCtD
Dabrafenib—Abdominal pain lower—Telbivudine—hepatitis B	0.00897	0.0438	CcSEcCtD
Dabrafenib—Hypophosphataemia—Adefovir Dipivoxil—hepatitis B	0.00583	0.0285	CcSEcCtD
Dabrafenib—Creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00356	0.0174	CcSEcCtD
Dabrafenib—LIMK1—blood—hepatitis B	0.0034	0.128	CbGeAlD
Dabrafenib—Hyperkalaemia—Adefovir Dipivoxil—hepatitis B	0.00333	0.0163	CcSEcCtD
Dabrafenib—Cardiomyopathy—Lamivudine—hepatitis B	0.00314	0.0153	CcSEcCtD
Dabrafenib—SLCO1B1—blood plasma—hepatitis B	0.00286	0.108	CbGeAlD
Dabrafenib—Gingival bleeding—Lamivudine—hepatitis B	0.00283	0.0138	CcSEcCtD
Dabrafenib—Influenza like illness—Telbivudine—hepatitis B	0.00277	0.0135	CcSEcCtD
Dabrafenib—Folliculitis—Lamivudine—hepatitis B	0.00256	0.0125	CcSEcCtD
Dabrafenib—Blood creatinine increased—Entecavir—hepatitis B	0.00236	0.0115	CcSEcCtD
Dabrafenib—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00231	0.0112	CcSEcCtD
Dabrafenib—Abdominal pain upper—Entecavir—hepatitis B	0.0023	0.0112	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.00217	0.0106	CcSEcCtD
Dabrafenib—Pancreatitis—Entecavir—hepatitis B	0.00214	0.0104	CcSEcCtD
Dabrafenib—BRAF—blood—hepatitis B	0.0021	0.0791	CbGeAlD
Dabrafenib—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.00208	0.0102	CcSEcCtD
Dabrafenib—Pain in extremity—Telbivudine—hepatitis B	0.00207	0.0101	CcSEcCtD
Dabrafenib—Neutropenia—Entecavir—hepatitis B	0.00204	0.00995	CcSEcCtD
Dabrafenib—Hyperglycaemia—Entecavir—hepatitis B	0.00197	0.00959	CcSEcCtD
Dabrafenib—Renal failure—Entecavir—hepatitis B	0.00191	0.00932	CcSEcCtD
Dabrafenib—Abdominal pain upper—Telbivudine—hepatitis B	0.00189	0.00923	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.00187	0.0091	CcSEcCtD
Dabrafenib—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00186	0.0091	CcSEcCtD
Dabrafenib—Haematuria—Entecavir—hepatitis B	0.00185	0.00904	CcSEcCtD
Dabrafenib—Nasopharyngitis—Telbivudine—hepatitis B	0.00185	0.00904	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.00183	0.00892	CcSEcCtD
Dabrafenib—Haematuria—Adefovir Dipivoxil—hepatitis B	0.00181	0.00882	CcSEcCtD
Dabrafenib—Bone disorder—Lamivudine—hepatitis B	0.00178	0.00869	CcSEcCtD
Dabrafenib—Oropharyngeal pain—Lamivudine—hepatitis B	0.00177	0.00863	CcSEcCtD
Dabrafenib—SIK1—blood—hepatitis B	0.00176	0.0662	CbGeAlD
Dabrafenib—Oedema peripheral—Entecavir—hepatitis B	0.00172	0.00839	CcSEcCtD
Dabrafenib—Abdominal discomfort—Telbivudine—hepatitis B	0.00172	0.00838	CcSEcCtD
Dabrafenib—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00168	0.0082	CcSEcCtD
Dabrafenib—Neutropenia—Telbivudine—hepatitis B	0.00167	0.00817	CcSEcCtD
Dabrafenib—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00167	0.00816	CcSEcCtD
Dabrafenib—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00167	0.00814	CcSEcCtD
Dabrafenib—BRAF—liver—hepatitis B	0.00164	0.0619	CbGeAlD
Dabrafenib—CYP2C8—blood plasma—hepatitis B	0.00163	0.0612	CbGeAlD
Dabrafenib—Immune system disorder—Entecavir—hepatitis B	0.00158	0.00769	CcSEcCtD
Dabrafenib—Renal failure—Telbivudine—hepatitis B	0.00157	0.00766	CcSEcCtD
Dabrafenib—Alopecia—Entecavir—hepatitis B	0.00154	0.00752	CcSEcCtD
Dabrafenib—Mental disorder—Entecavir—hepatitis B	0.00153	0.00746	CcSEcCtD
Dabrafenib—Malnutrition—Entecavir—hepatitis B	0.00152	0.00741	CcSEcCtD
Dabrafenib—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.00148	0.00723	CcSEcCtD
Dabrafenib—Back pain—Adefovir Dipivoxil—hepatitis B	0.00143	0.00699	CcSEcCtD
Dabrafenib—SLCO1B3—liver—hepatitis B	0.00142	0.0533	CbGeAlD
Dabrafenib—Connective tissue disorder—Telbivudine—hepatitis B	0.00141	0.00687	CcSEcCtD
Dabrafenib—RAF1—blood—hepatitis B	0.0014	0.0527	CbGeAlD
Dabrafenib—SIK1—liver—hepatitis B	0.00137	0.0518	CbGeAlD
Dabrafenib—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00137	0.00668	CcSEcCtD
Dabrafenib—Leukopenia—Entecavir—hepatitis B	0.00136	0.00663	CcSEcCtD
Dabrafenib—Cough—Adefovir Dipivoxil—hepatitis B	0.00129	0.00631	CcSEcCtD
Dabrafenib—Mediastinal disorder—Telbivudine—hepatitis B	0.00129	0.0063	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00128	0.00627	CcSEcCtD
Dabrafenib—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00126	0.00616	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00125	0.00611	CcSEcCtD
Dabrafenib—Malnutrition—Telbivudine—hepatitis B	0.00125	0.00609	CcSEcCtD
Dabrafenib—Infection—Entecavir—hepatitis B	0.00123	0.00601	CcSEcCtD
Dabrafenib—Nervous system disorder—Entecavir—hepatitis B	0.00122	0.00593	CcSEcCtD
Dabrafenib—Back pain—Telbivudine—hepatitis B	0.00121	0.00589	CcSEcCtD
Dabrafenib—Skin disorder—Entecavir—hepatitis B	0.0012	0.00587	CcSEcCtD
Dabrafenib—Muscle spasms—Telbivudine—hepatitis B	0.0012	0.00585	CcSEcCtD
Dabrafenib—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00119	0.00579	CcSEcCtD
Dabrafenib—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.00118	0.00578	CcSEcCtD
Dabrafenib—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00117	0.00573	CcSEcCtD
Dabrafenib—Insomnia—Entecavir—hepatitis B	0.00112	0.00547	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.0011	0.00538	CcSEcCtD
Dabrafenib—CYP3A4—blood plasma—hepatitis B	0.0011	0.0415	CbGeAlD
Dabrafenib—RAF1—liver—hepatitis B	0.00109	0.0412	CbGeAlD
Dabrafenib—Cough—Telbivudine—hepatitis B	0.00109	0.00531	CcSEcCtD
Dabrafenib—Dehydration—Lamivudine—hepatitis B	0.00109	0.0053	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Entecavir—hepatitis B	0.00107	0.00522	CcSEcCtD
Dabrafenib—Fatigue—Entecavir—hepatitis B	0.00107	0.00521	CcSEcCtD
Dabrafenib—Abdominal pain upper—Lamivudine—hepatitis B	0.00107	0.0052	CcSEcCtD
Dabrafenib—Arthralgia—Telbivudine—hepatitis B	0.00106	0.00518	CcSEcCtD
Dabrafenib—Myalgia—Telbivudine—hepatitis B	0.00106	0.00518	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00105	0.00515	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.00105	0.00513	CcSEcCtD
Dabrafenib—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00105	0.00513	CcSEcCtD
Dabrafenib—SLCO1B1—blood—hepatitis B	0.00105	0.0394	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00104	0.00509	CcSEcCtD
Dabrafenib—Nasopharyngitis—Lamivudine—hepatitis B	0.00104	0.00509	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.00103	0.00502	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Entecavir—hepatitis B	0.00101	0.00495	CcSEcCtD
Dabrafenib—Nervous system disorder—Telbivudine—hepatitis B	0.000999	0.00487	CcSEcCtD
Dabrafenib—Thrombocytopenia—Telbivudine—hepatitis B	0.000997	0.00486	CcSEcCtD
Dabrafenib—Pancreatitis—Lamivudine—hepatitis B	0.000989	0.00483	CcSEcCtD
Dabrafenib—Skin disorder—Telbivudine—hepatitis B	0.000989	0.00483	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.000989	0.00483	CcSEcCtD
Dabrafenib—Abdominal pain—Entecavir—hepatitis B	0.00098	0.00478	CcSEcCtD
Dabrafenib—Body temperature increased—Entecavir—hepatitis B	0.00098	0.00478	CcSEcCtD
Dabrafenib—Abdominal discomfort—Lamivudine—hepatitis B	0.000967	0.00472	CcSEcCtD
Dabrafenib—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.000956	0.00466	CcSEcCtD
Dabrafenib—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.000956	0.00466	CcSEcCtD
Dabrafenib—Neutropenia—Lamivudine—hepatitis B	0.000944	0.0046	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.000928	0.00453	CcSEcCtD
Dabrafenib—Insomnia—Telbivudine—hepatitis B	0.000921	0.00449	CcSEcCtD
Dabrafenib—Hyperglycaemia—Lamivudine—hepatitis B	0.00091	0.00444	CcSEcCtD
Dabrafenib—Asthenia—Entecavir—hepatitis B	0.000889	0.00434	CcSEcCtD
Dabrafenib—Renal failure—Lamivudine—hepatitis B	0.000884	0.00432	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Telbivudine—hepatitis B	0.000879	0.00429	CcSEcCtD
Dabrafenib—Fatigue—Telbivudine—hepatitis B	0.000878	0.00428	CcSEcCtD
Dabrafenib—Stomatitis—Lamivudine—hepatitis B	0.000877	0.00428	CcSEcCtD
Dabrafenib—Asthenia—Adefovir Dipivoxil—hepatitis B	0.000868	0.00423	CcSEcCtD
Dabrafenib—Pruritus—Adefovir Dipivoxil—hepatitis B	0.000856	0.00417	CcSEcCtD
Dabrafenib—Epistaxis—Lamivudine—hepatitis B	0.000849	0.00414	CcSEcCtD
Dabrafenib—Diarrhoea—Entecavir—hepatitis B	0.000848	0.00414	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Telbivudine—hepatitis B	0.000833	0.00406	CcSEcCtD
Dabrafenib—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.000827	0.00404	CcSEcCtD
Dabrafenib—Dizziness—Entecavir—hepatitis B	0.00082	0.004	CcSEcCtD
Dabrafenib—SLCO1B1—liver—hepatitis B	0.000819	0.0308	CbGeAlD
Dabrafenib—SLC22A8—blood—hepatitis B	0.000814	0.0306	CbGeAlD
Dabrafenib—Abdominal pain—Telbivudine—hepatitis B	0.000805	0.00393	CcSEcCtD
Dabrafenib—Body temperature increased—Telbivudine—hepatitis B	0.000805	0.00393	CcSEcCtD
Dabrafenib—Connective tissue disorder—Lamivudine—hepatitis B	0.000794	0.00387	CcSEcCtD
Dabrafenib—Vomiting—Entecavir—hepatitis B	0.000788	0.00385	CcSEcCtD
Dabrafenib—Rash—Entecavir—hepatitis B	0.000781	0.00381	CcSEcCtD
Dabrafenib—Dermatitis—Entecavir—hepatitis B	0.000781	0.00381	CcSEcCtD
Dabrafenib—ABCB1—blood plasma—hepatitis B	0.000779	0.0294	CbGeAlD
Dabrafenib—Headache—Entecavir—hepatitis B	0.000776	0.00379	CcSEcCtD
Dabrafenib—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000769	0.00375	CcSEcCtD
Dabrafenib—Rash—Adefovir Dipivoxil—hepatitis B	0.000762	0.00372	CcSEcCtD
Dabrafenib—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.000762	0.00372	CcSEcCtD
Dabrafenib—Headache—Adefovir Dipivoxil—hepatitis B	0.000758	0.0037	CcSEcCtD
Dabrafenib—Nausea—Entecavir—hepatitis B	0.000736	0.00359	CcSEcCtD
Dabrafenib—Asthenia—Telbivudine—hepatitis B	0.000731	0.00356	CcSEcCtD
Dabrafenib—Immune system disorder—Lamivudine—hepatitis B	0.00073	0.00356	CcSEcCtD
Dabrafenib—Mediastinal disorder—Lamivudine—hepatitis B	0.000728	0.00355	CcSEcCtD
Dabrafenib—Chills—Lamivudine—hepatitis B	0.000725	0.00354	CcSEcCtD
Dabrafenib—Pruritus—Telbivudine—hepatitis B	0.00072	0.00352	CcSEcCtD
Dabrafenib—Nausea—Adefovir Dipivoxil—hepatitis B	0.000718	0.00351	CcSEcCtD
Dabrafenib—Alopecia—Lamivudine—hepatitis B	0.000714	0.00348	CcSEcCtD
Dabrafenib—Erythema—Lamivudine—hepatitis B	0.000703	0.00343	CcSEcCtD
Dabrafenib—Malnutrition—Lamivudine—hepatitis B	0.000703	0.00343	CcSEcCtD
Dabrafenib—Diarrhoea—Telbivudine—hepatitis B	0.000697	0.0034	CcSEcCtD
Dabrafenib—Back pain—Lamivudine—hepatitis B	0.00068	0.00332	CcSEcCtD
Dabrafenib—Muscle spasms—Lamivudine—hepatitis B	0.000676	0.0033	CcSEcCtD
Dabrafenib—Dizziness—Telbivudine—hepatitis B	0.000673	0.00329	CcSEcCtD
Dabrafenib—Anaemia—Lamivudine—hepatitis B	0.00065	0.00317	CcSEcCtD
Dabrafenib—Vomiting—Telbivudine—hepatitis B	0.000647	0.00316	CcSEcCtD
Dabrafenib—Rash—Telbivudine—hepatitis B	0.000642	0.00313	CcSEcCtD
Dabrafenib—Dermatitis—Telbivudine—hepatitis B	0.000641	0.00313	CcSEcCtD
Dabrafenib—Headache—Telbivudine—hepatitis B	0.000638	0.00311	CcSEcCtD
Dabrafenib—Leukopenia—Lamivudine—hepatitis B	0.000629	0.00307	CcSEcCtD
Dabrafenib—Cough—Lamivudine—hepatitis B	0.000614	0.00299	CcSEcCtD
Dabrafenib—Nausea—Telbivudine—hepatitis B	0.000605	0.00295	CcSEcCtD
Dabrafenib—Myalgia—Lamivudine—hepatitis B	0.000599	0.00292	CcSEcCtD
Dabrafenib—Arthralgia—Lamivudine—hepatitis B	0.000599	0.00292	CcSEcCtD
Dabrafenib—CYP2C8—blood—hepatitis B	0.000595	0.0224	CbGeAlD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000594	0.0029	CcSEcCtD
Dabrafenib—Dry mouth—Lamivudine—hepatitis B	0.000585	0.00286	CcSEcCtD
Dabrafenib—ABCG2—blood—hepatitis B	0.000579	0.0218	CbGeAlD
Dabrafenib—Oedema—Lamivudine—hepatitis B	0.000574	0.0028	CcSEcCtD
Dabrafenib—Infection—Lamivudine—hepatitis B	0.00057	0.00278	CcSEcCtD
Dabrafenib—Nervous system disorder—Lamivudine—hepatitis B	0.000563	0.00275	CcSEcCtD
Dabrafenib—Thrombocytopenia—Lamivudine—hepatitis B	0.000562	0.00274	CcSEcCtD
Dabrafenib—Skin disorder—Lamivudine—hepatitis B	0.000557	0.00272	CcSEcCtD
Dabrafenib—Hyperhidrosis—Lamivudine—hepatitis B	0.000555	0.00271	CcSEcCtD
Dabrafenib—Hypotension—Lamivudine—hepatitis B	0.000536	0.00262	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000523	0.00255	CcSEcCtD
Dabrafenib—Insomnia—Lamivudine—hepatitis B	0.000519	0.00253	CcSEcCtD
Dabrafenib—Decreased appetite—Lamivudine—hepatitis B	0.000499	0.00243	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000495	0.00242	CcSEcCtD
Dabrafenib—Fatigue—Lamivudine—hepatitis B	0.000495	0.00241	CcSEcCtD
Dabrafenib—Constipation—Lamivudine—hepatitis B	0.000491	0.00239	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Lamivudine—hepatitis B	0.000469	0.00229	CcSEcCtD
Dabrafenib—CYP2C8—liver—hepatitis B	0.000466	0.0175	CbGeAlD
Dabrafenib—Abdominal pain—Lamivudine—hepatitis B	0.000454	0.00221	CcSEcCtD
Dabrafenib—Body temperature increased—Lamivudine—hepatitis B	0.000454	0.00221	CcSEcCtD
Dabrafenib—ABCG2—liver—hepatitis B	0.000453	0.0171	CbGeAlD
Dabrafenib—Hypersensitivity—Lamivudine—hepatitis B	0.000423	0.00206	CcSEcCtD
Dabrafenib—Asthenia—Lamivudine—hepatitis B	0.000412	0.00201	CcSEcCtD
Dabrafenib—Pruritus—Lamivudine—hepatitis B	0.000406	0.00198	CcSEcCtD
Dabrafenib—CYP3A4—blood—hepatitis B	0.000403	0.0152	CbGeAlD
Dabrafenib—Diarrhoea—Lamivudine—hepatitis B	0.000393	0.00192	CcSEcCtD
Dabrafenib—Dizziness—Lamivudine—hepatitis B	0.000379	0.00185	CcSEcCtD
Dabrafenib—Vomiting—Lamivudine—hepatitis B	0.000365	0.00178	CcSEcCtD
Dabrafenib—Rash—Lamivudine—hepatitis B	0.000362	0.00177	CcSEcCtD
Dabrafenib—Dermatitis—Lamivudine—hepatitis B	0.000361	0.00176	CcSEcCtD
Dabrafenib—Headache—Lamivudine—hepatitis B	0.000359	0.00175	CcSEcCtD
Dabrafenib—Nausea—Lamivudine—hepatitis B	0.000341	0.00166	CcSEcCtD
Dabrafenib—CYP3A4—liver—hepatitis B	0.000315	0.0119	CbGeAlD
Dabrafenib—ABCB1—blood—hepatitis B	0.000285	0.0108	CbGeAlD
Dabrafenib—ABCB1—liver—hepatitis B	0.000223	0.00841	CbGeAlD
Dabrafenib—RAF1—Innate Immune System—IFNA1—hepatitis B	7.39e-05	0.000679	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—ALB—hepatitis B	7.39e-05	0.000679	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NFKB1—hepatitis B	7.37e-05	0.000677	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—CDKN1A—hepatitis B	7.35e-05	0.000676	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—PTEN—hepatitis B	7.34e-05	0.000674	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—CDKN1A—hepatitis B	7.31e-05	0.000671	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—PTEN—hepatitis B	7.29e-05	0.00067	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—hepatitis B	7.29e-05	0.00067	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—CDKN1A—hepatitis B	7.29e-05	0.00067	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—PTEN—hepatitis B	7.27e-05	0.000668	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—CDKN1A—hepatitis B	7.26e-05	0.000667	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—NFKB1—hepatitis B	7.25e-05	0.000667	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—PTEN—hepatitis B	7.24e-05	0.000665	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—CTNNB1—hepatitis B	7.18e-05	0.00066	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—IL6—hepatitis B	7.18e-05	0.000659	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	7.15e-05	0.000657	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2—hepatitis B	7.08e-05	0.00065	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—hepatitis B	7.02e-05	0.000645	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—PTEN—hepatitis B	7e-05	0.000643	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	6.98e-05	0.000642	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MX1—hepatitis B	6.98e-05	0.000641	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	6.97e-05	0.00064	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—CYP2A6—hepatitis B	6.95e-05	0.000638	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	6.93e-05	0.000637	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—hepatitis B	6.92e-05	0.000636	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IFNA2—hepatitis B	6.88e-05	0.000632	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD14—hepatitis B	6.88e-05	0.000632	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—hepatitis B	6.87e-05	0.000631	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	6.75e-05	0.000621	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—ALB—hepatitis B	6.72e-05	0.000618	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—hepatitis B	6.69e-05	0.000614	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKR1B1—hepatitis B	6.63e-05	0.000609	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2—hepatitis B	6.59e-05	0.000605	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—CDKN1A—hepatitis B	6.57e-05	0.000604	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—PTEN—hepatitis B	6.56e-05	0.000603	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—hepatitis B	6.53e-05	0.0006	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SAG—hepatitis B	6.51e-05	0.000598	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RIT2—hepatitis B	6.51e-05	0.000598	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—hepatitis B	6.49e-05	0.000596	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TGFB1—hepatitis B	6.4e-05	0.000588	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—hepatitis B	6.39e-05	0.000587	CbGpPWpGaD
Dabrafenib—BRAF—Disease—GOT2—hepatitis B	6.38e-05	0.000587	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GGT2—hepatitis B	6.36e-05	0.000584	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	6.21e-05	0.000571	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKR1B1—hepatitis B	6.14e-05	0.000564	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—hepatitis B	6.14e-05	0.000564	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	5.99e-05	0.00055	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—hepatitis B	5.98e-05	0.000549	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—hepatitis B	5.92e-05	0.000544	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GGT2—hepatitis B	5.89e-05	0.000541	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—hepatitis B	5.88e-05	0.000541	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—hepatitis B	5.79e-05	0.000532	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	5.78e-05	0.000531	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP2A6—hepatitis B	5.73e-05	0.000527	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40LG—hepatitis B	5.62e-05	0.000516	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—hepatitis B	5.6e-05	0.000514	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—hepatitis B	5.56e-05	0.000511	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—hepatitis B	5.55e-05	0.00051	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TGFB1—hepatitis B	5.52e-05	0.000507	CbGpPWpGaD
Dabrafenib—BRAF—Disease—GOT1—hepatitis B	5.51e-05	0.000506	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—hepatitis B	5.45e-05	0.000501	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GGT1—hepatitis B	5.42e-05	0.000498	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	5.39e-05	0.000496	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—hepatitis B	5.35e-05	0.000491	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—hepatitis B	5.31e-05	0.000488	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—hepatitis B	5.27e-05	0.000484	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—hepatitis B	5.22e-05	0.00048	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—hepatitis B	5.2e-05	0.000477	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GOT2—hepatitis B	5.18e-05	0.000476	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—hepatitis B	5.15e-05	0.000474	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—hepatitis B	5.15e-05	0.000473	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—hepatitis B	5.14e-05	0.000472	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NFKB1—hepatitis B	5.11e-05	0.000469	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—hepatitis B	5.08e-05	0.000467	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CDKN1A—hepatitis B	5.06e-05	0.000465	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—PTEN—hepatitis B	5.04e-05	0.000464	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—F2—hepatitis B	5.04e-05	0.000463	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NFKB1—hepatitis B	5.02e-05	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—hepatitis B	4.99e-05	0.000459	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS2—hepatitis B	4.98e-05	0.000458	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CTNNB1—hepatitis B	4.97e-05	0.000457	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—hepatitis B	4.96e-05	0.000456	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-A—hepatitis B	4.95e-05	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—hepatitis B	4.94e-05	0.000454	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—hepatitis B	4.92e-05	0.000452	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HSPA5—hepatitis B	4.89e-05	0.00045	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CDKN1A—hepatitis B	4.85e-05	0.000446	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PTEN—hepatitis B	4.84e-05	0.000445	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NFKB1—hepatitis B	4.82e-05	0.000443	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	4.75e-05	0.000437	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TLR4—hepatitis B	4.72e-05	0.000433	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—hepatitis B	4.63e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—hepatitis B	4.63e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—hepatitis B	4.63e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DPB1—hepatitis B	4.62e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—hepatitis B	4.58e-05	0.000421	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—hepatitis B	4.55e-05	0.000419	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—hepatitis B	4.54e-05	0.000418	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-DRB1—hepatitis B	4.52e-05	0.000416	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—hepatitis B	4.52e-05	0.000416	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—hepatitis B	4.5e-05	0.000413	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GGT1—hepatitis B	4.48e-05	0.000411	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GOT1—hepatitis B	4.48e-05	0.000411	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR2—hepatitis B	4.45e-05	0.000409	CbGpPWpGaD
Dabrafenib—RAF1—Disease—GOT2—hepatitis B	4.42e-05	0.000406	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNB1—hepatitis B	4.41e-05	0.000406	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL10—hepatitis B	4.35e-05	0.0004	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNA1—hepatitis B	4.31e-05	0.000396	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—hepatitis B	4.19e-05	0.000385	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCR5—hepatitis B	4.11e-05	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—hepatitis B	4.1e-05	0.000376	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	4.08e-05	0.000375	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HLA-A—hepatitis B	4.01e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD14—hepatitis B	4.01e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNA2—hepatitis B	4.01e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hepatitis B	3.96e-05	0.000364	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	3.88e-05	0.000357	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP2A6—hepatitis B	3.85e-05	0.000354	CbGpPWpGaD
Dabrafenib—RAF1—Disease—GOT1—hepatitis B	3.81e-05	0.00035	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKR1B1—hepatitis B	3.81e-05	0.00035	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—hepatitis B	3.75e-05	0.000345	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL10—hepatitis B	3.71e-05	0.000341	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GGT2—hepatitis B	3.65e-05	0.000336	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—hepatitis B	3.63e-05	0.000333	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—hepatitis B	3.59e-05	0.00033	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP2A6—hepatitis B	3.57e-05	0.000328	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—hepatitis B	3.49e-05	0.00032	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GOT2—hepatitis B	3.48e-05	0.00032	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL18—hepatitis B	3.42e-05	0.000314	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—hepatitis B	3.42e-05	0.000314	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—hepatitis B	3.41e-05	0.000313	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—hepatitis B	3.4e-05	0.000312	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—hepatitis B	3.37e-05	0.00031	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	3.37e-05	0.00031	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—hepatitis B	3.37e-05	0.00031	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CTNNB1—hepatitis B	3.34e-05	0.000307	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—hepatitis B	3.32e-05	0.000305	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKR1B1—hepatitis B	3.32e-05	0.000305	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	3.29e-05	0.000303	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	3.29e-05	0.000302	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	3.27e-05	0.0003	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NFKB1—hepatitis B	3.24e-05	0.000298	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GOT2—hepatitis B	3.23e-05	0.000296	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—hepatitis B	3.2e-05	0.000295	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—hepatitis B	3.19e-05	0.000293	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GGT2—hepatitis B	3.18e-05	0.000293	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—hepatitis B	3.16e-05	0.000291	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—hepatitis B	3.15e-05	0.00029	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—hepatitis B	3.03e-05	0.000278	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GOT1—hepatitis B	3.01e-05	0.000276	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GGT1—hepatitis B	3.01e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-A—hepatitis B	3e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—hepatitis B	2.95e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—F2—hepatitis B	2.89e-05	0.000266	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1A—hepatitis B	2.88e-05	0.000265	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—hepatitis B	2.88e-05	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PTEN—hepatitis B	2.88e-05	0.000264	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NFKB1—hepatitis B	2.86e-05	0.000263	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—hepatitis B	2.85e-05	0.000262	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—hepatitis B	2.85e-05	0.000262	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GGT1—hepatitis B	2.78e-05	0.000256	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GOT1—hepatitis B	2.78e-05	0.000256	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HLA-A—hepatitis B	2.77e-05	0.000255	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1A—hepatitis B	2.77e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTEN—hepatitis B	2.76e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NFKB1—hepatitis B	2.75e-05	0.000253	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—hepatitis B	2.75e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DRB1—hepatitis B	2.74e-05	0.000252	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.74e-05	0.000252	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	2.72e-05	0.00025	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—hepatitis B	2.7e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—hepatitis B	2.65e-05	0.000243	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—hepatitis B	2.58e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL10—hepatitis B	2.57e-05	0.000236	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	2.54e-05	0.000234	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—hepatitis B	2.52e-05	0.000232	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—F2—hepatitis B	2.47e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—hepatitis B	2.41e-05	0.000222	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—hepatitis B	2.38e-05	0.000219	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—hepatitis B	2.29e-05	0.000211	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	2.24e-05	0.000206	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1A—hepatitis B	2.24e-05	0.000206	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTEN—hepatitis B	2.24e-05	0.000205	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2A6—hepatitis B	2.21e-05	0.000203	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—hepatitis B	2.18e-05	0.0002	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.06e-05	0.00019	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1B1—hepatitis B	2.05e-05	0.000188	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—hepatitis B	2.03e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—hepatitis B	2e-05	0.000184	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT2—hepatitis B	2e-05	0.000184	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—hepatitis B	1.99e-05	0.000183	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GGT2—hepatitis B	1.96e-05	0.00018	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—hepatitis B	1.95e-05	0.000179	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—hepatitis B	1.94e-05	0.000178	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2A6—hepatitis B	1.93e-05	0.000177	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—hepatitis B	1.85e-05	0.00017	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—hepatitis B	1.82e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—hepatitis B	1.8e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—hepatitis B	1.79e-05	0.000164	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—hepatitis B	1.78e-05	0.000164	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT2—hepatitis B	1.74e-05	0.00016	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT1—hepatitis B	1.73e-05	0.000159	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GGT1—hepatitis B	1.73e-05	0.000159	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—hepatitis B	1.72e-05	0.000158	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—hepatitis B	1.71e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—hepatitis B	1.71e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—hepatitis B	1.68e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—hepatitis B	1.68e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKB1—hepatitis B	1.67e-05	0.000153	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—hepatitis B	1.66e-05	0.000153	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—hepatitis B	1.61e-05	0.000148	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—hepatitis B	1.6e-05	0.000147	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—hepatitis B	1.59e-05	0.000146	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.57e-05	0.000145	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—hepatitis B	1.57e-05	0.000144	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—hepatitis B	1.57e-05	0.000144	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKB1—hepatitis B	1.56e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—hepatitis B	1.55e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—hepatitis B	1.55e-05	0.000142	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GGT1—hepatitis B	1.51e-05	0.000138	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT1—hepatitis B	1.51e-05	0.000138	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—hepatitis B	1.48e-05	0.000136	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—hepatitis B	1.4e-05	0.000128	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—hepatitis B	1.3e-05	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—hepatitis B	1.28e-05	0.000118	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—hepatitis B	1.22e-05	0.000112	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2A6—hepatitis B	1.19e-05	0.000109	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—hepatitis B	1.15e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—hepatitis B	1.15e-05	0.000105	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—hepatitis B	1.13e-05	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—hepatitis B	1.11e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—hepatitis B	1.09e-05	9.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—hepatitis B	1.08e-05	9.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKB1—hepatitis B	1.08e-05	9.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT2—hepatitis B	1.07e-05	9.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—hepatitis B	1.07e-05	9.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—hepatitis B	1.05e-05	9.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—hepatitis B	9.78e-06	8.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—hepatitis B	9.66e-06	8.88e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT1—hepatitis B	9.27e-06	8.52e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GGT1—hepatitis B	9.27e-06	8.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—hepatitis B	9.19e-06	8.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—hepatitis B	8.98e-06	8.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—hepatitis B	8.01e-06	7.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—hepatitis B	7.39e-06	6.79e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—hepatitis B	7.01e-06	6.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—hepatitis B	6.77e-06	6.22e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—hepatitis B	6.11e-06	5.61e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—hepatitis B	4.93e-06	4.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—hepatitis B	3.76e-06	3.46e-05	CbGpPWpGaD
